SCHEMBL13735409

SCHEMBL13735409

Fc1[c]ccc(-n2ccnc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.47
CYP11B2 P19099 3/20 0.47
CYP19A1 P11511 2/20 0.47
IDO1 P14902 1/20 0.47
CYP3A4 P08684 3/20 0.47
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
ENPP2 Q13822 1/20 0.44
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
NOTUM Q6P988 1/20 0.44
CYP2A6 P11509 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
BAZ2B Q9UIF8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29001785 0.81 IDO1 (0.57) CYP11B1CYP11B2CYP19A1IDO1CYP3A4
SCHEMBL7393053 0.79 CYP11B1 (0.51) CYP11B1CYP11B2CYP19A1IDO1CYP3A4
SCHEMBL25268906 0.79 CYP11B1 (0.47) CYP11B1CYP11B2CYP19A1IDO1CYP3A4
SCHEMBL20506488 0.79 CYP19A1 (0.44) CYP11B1CYP11B2CYP19A1IDO1CYP3A4
SCHEMBL13734223 0.78 CYP1A2 (0.34)
SCHEMBL243161 0.77 CYP11B1 (0.55) CYP11B1CYP11B2CYP19A1IDO1CYP3A4
SCHEMBL13733386 0.76 MAPT (0.41) LMNAMAPTMEN1KMT2A
SCHEMBL161573 0.74 CYP3A4 (0.63) CYP11B1CYP11B2CYP19A1IDO1CYP3A4
SCHEMBL9584700 0.72 CYP11B1 (0.41) CYP11B1CYP11B2CYP19A1IDO1CYP3A4
SCHEMBL28046790 0.72 CYP3A4 (0.61) CYP11B1CYP11B2CYP19A1IDO1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2014-03-06 US claimed
WO-2012145361-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2012-10-26 WO claimed
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2014-03-06 US disclosed
WO-2012145361-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2012-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto GPR119, GLP1R, SLC5A2 CYP11B1 2611/4885CYP11B2 2283/4885CYP19A1 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.